2022 World Conference on Lung Cancer (ePosters)-EP08.02-134. Real-world Efficacy of Dacomitinib in Patients with Previously EGFR-TKI Treated Non-small Cell Lung Cancer

EP08.02-134. Real-world Efficacy of Dacomitinib in Patients with Previously EGFR-TKI Treated Non-small Cell Lung Cancer

Pdf Summary

A study was conducted to assess the real-world efficacy of dacomitinib in patients with previously treated non-small cell lung cancer (NSCLC) who had received EGFR-tyrosine kinase inhibitor (TKI) therapy. The study enrolled 21 patients who had progressed on previous EGFR-TKI and chemotherapy, and they were treated with dacomitinib orally daily until disease progression or intolerability. The results showed that the duration of response was 4.6 months, with partial responses observed in patients with original sensitizing EGFR mutations. However, patients with acquired EGFR resistance mutations did not meet the response criteria.<br /><br />The median progression-free survival (PFS), time to treatment failure (TTF), and overall survival (OS) from dacomitinib initiation were 1.6 months, 1.87 months, and 10.2 months, respectively. Among the patients with brain metastases, one partial intracranial response was recorded. The study found that dacomitinib in previously EGFR-TKI treated NSCLC had limited benefit in real-world practice, with higher risks of disease progression, treatment failure, and death observed in patients with worse performance status. The study also compared the outcomes in patients with different Eastern Cooperative Oncology Group (ECOG) performance statuses and found that patients with an ECOG PS of 2 had significantly shorter PFS, TTF, and OS compared to those with an ECOG PS of 1.<br /><br />In conclusion, the study demonstrated that dacomitinib had limited efficacy in previously EGFR-TKI treated NSCLC in real-world practice. The efficacy varied based on the type of EGFR mutation and the patient's performance status. These findings provide important insights into the use of dacomitinib in this patient population.

Asset Subtitle

Chien-Yeh Chi

Meta Tag

Speaker Chien-Yeh Chi

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

dacomitinib

non-small cell lung cancer

NSCLC

EGFR-tyrosine kinase inhibitor

TKI therapy

response duration

EGFR mutations

acquired resistance mutations

progression-free survival

Eastern Cooperative Oncology Group